Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Lantheus Holdings, Inc. | d219054dex991.htm |
8-K - FORM 8-K - Lantheus Holdings, Inc. | d219054d8k.htm |
Exhibit 99.2
LANTHEUS HOLDINGS, INC. AND SUBSIDARIES
UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET
JUNE 30, 2016
(in thousands, except share data) |
As Reported | Pro Forma Adjustments (1) |
Pro Forma As Adjusted |
|||||||||
Assets |
||||||||||||
Current assets |
||||||||||||
Cash and cash equivalents |
$ | 54,851 | $ | 1,237 | $ | 56,088 | ||||||
Accounts receivable, net |
39,457 | (1,639 | ) | 37,818 | ||||||||
Inventory |
14,433 | (394 | ) | 14,039 | ||||||||
Other current assets |
4,282 | (189 | ) | 4,093 | ||||||||
|
|
|
|
|
|
|||||||
Total current assets |
113,023 | (985 | ) | 112,038 | ||||||||
Property, plant and equipment, net |
84,422 | (1 | ) | 84,421 | ||||||||
Capitalized software development costs, net |
8,121 | | 8,121 | |||||||||
Intangibles, net |
17,949 | (260 | ) | 17,689 | ||||||||
Goodwill |
15,714 | | 15,714 | |||||||||
Other long-term assets |
20,038 | (47 | ) | 19,991 | ||||||||
|
|
|
|
|
|
|||||||
Total assets |
$ | 259,267 | $ | (1,293 | ) | $ | 257,974 | |||||
|
|
|
|
|
|
|||||||
Liabilities and Stockholders Deficit |
||||||||||||
Current liabilities |
||||||||||||
Line of credit |
| | | |||||||||
Accounts payable |
12,778 | (489 | ) | 12,289 | ||||||||
Accrued expenses and other liabilities |
17,664 | (426 | ) | 17,238 | ||||||||
Current portion of long-term debt |
3,650 | | 3,650 | |||||||||
|
|
|
|
|
|
|||||||
Total current liabilities |
34,092 | (915 | ) | 33,177 | ||||||||
Asset retirement obligations |
8,650 | | 8,650 | |||||||||
Long-term debt, net |
348,838 | | 348,838 | |||||||||
Other long-term liabilities |
34,055 | 82 | 34,137 | |||||||||
|
|
|
|
|
|
|||||||
Total liabilities |
425,635 | (833 | ) | 424,802 | ||||||||
|
|
|
|
|
|
|||||||
Commitments and contingencies |
||||||||||||
Stockholders deficit |
||||||||||||
Preferred stock |
| | | |||||||||
Common stock |
303 | | 303 | |||||||||
Additional paid-in capital |
176,545 | | 176,545 | |||||||||
Accumulated deficit |
(341,487 | ) | (1,041 | ) | (342,528 | ) | ||||||
Accumulated other comprehensive loss |
(1,729 | ) | 581 | (1,148 | ) | |||||||
|
|
|
|
|
|
|||||||
Total stockholders deficit |
(166,368 | ) | (460 | ) | (166,828 | ) | ||||||
|
|
|
|
|
|
|||||||
Total liabilities and stockholders deficit |
$ | 259,267 | $ | (1,293 | ) | $ | 257,974 | |||||
|
|
|
|
|
|
1
LANTHEUS HOLDINGS, INC. AND SUBSIDARIES
UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS
SIX MONTHS ENDED JUNE 30, 2016
(in thousands, except per share data) |
As Reported | Pro Forma Adjustments (2)(3) |
Pro Forma As Adjusted |
|||||||||
Revenues |
$ | 154,440 | $ | (4,834 | ) | $ | 149,606 | |||||
Cost of goods sold |
84,988 | (4,185 | ) | 80,803 | ||||||||
|
|
|
|
|
|
|||||||
Gross profit |
69,452 | (649 | ) | 68,803 | ||||||||
|
|
|
|
|
|
|||||||
Operating expenses |
||||||||||||
Sales and marketing expenses |
19,150 | (72 | ) | 19,078 | ||||||||
General and administrative expenses |
18,751 | (215 | ) | 18,536 | ||||||||
Research and development expenses |
5,644 | | 5,644 | |||||||||
|
|
|
|
|
|
|||||||
Total operating expenses |
43,545 | (287 | ) | 43,258 | ||||||||
Gain on sale of assets |
5,945 | | 5,945 | |||||||||
|
|
|
|
|
|
|||||||
Operating income |
31,852 | (362 | ) | 31,490 | ||||||||
Interest expense, net |
(13,996 | ) | | (13,996 | ) | |||||||
Other income, net |
454 | 45 | 499 | |||||||||
|
|
|
|
|
|
|||||||
Income before income taxes |
18,310 | (317 | ) | 17,993 | ||||||||
Provision for income taxes |
637 | 33 | 670 | |||||||||
|
|
|
|
|
|
|||||||
Net income |
17,673 | (350 | ) | 17,323 | ||||||||
|
|
|
|
|
|
|||||||
Net income per common share: |
||||||||||||
Basic |
$ | 0.58 | $ | 0.57 | ||||||||
Diluted |
$ | 0.58 | $ | 0.57 | ||||||||
Weighted average common shares outstanding |
||||||||||||
Basic |
30,373 | 30,373 | ||||||||||
Diluted |
30,454 | 30,454 |
2
LANTHEUS HOLDINGS, INC. AND SUBSIDARIES
UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS
YEAR ENDED DECEMBER 31, 2015
(in thousands, except per share data) |
As Reported | Pro Forma Adjustments (2)(3) |
Pro Forma As Adjusted |
|||||||||
Revenues |
$ | 293,461 | $ | (9,678 | ) | $ | 283,783 | |||||
Cost of goods sold |
157,939 | (7,977 | ) | 149,962 | ||||||||
|
|
|
|
|
|
|||||||
Gross profit |
135,522 | (1,701 | ) | 133,821 | ||||||||
|
|
|
|
|
|
|||||||
Operating expenses |
||||||||||||
Sales and marketing expenses |
34,740 | (134 | ) | 34,606 | ||||||||
General and administrative expenses |
43,894 | (322 | ) | 43,572 | ||||||||
Research and development expenses |
14,358 | | 14,358 | |||||||||
|
|
|
|
|
|
|||||||
Total operating expenses |
92,992 | (456 | ) | 92,536 | ||||||||
|
|
|
|
|
|
|||||||
Operating income |
42,530 | (1,245 | ) | 41,285 | ||||||||
Interest expense, net |
(38,691 | ) | | (38,691 | ) | |||||||
Loss on extinguisment of debt |
(15,528 | ) | | (15,528 | ) | |||||||
Other expense, net |
(89 | ) | (265 | ) | (354 | ) | ||||||
|
|
|
|
|
|
|||||||
Loss before income taxes |
(11,778 | ) | (1,510 | ) | (13,288 | ) | ||||||
Provision for income taxes |
2,968 | (325 | ) | 2,643 | ||||||||
|
|
|
|
|
|
|||||||
Net loss |
(14,746 | ) | (1,185 | ) | (15,931 | ) | ||||||
|
|
|
|
|
|
|||||||
Net loss per common share: |
||||||||||||
Basic and diluted |
$ | (0.60 | ) | $ | (0.65 | ) | ||||||
Weighted average common shares outstanding |
||||||||||||
Basic and diluted |
24,440 | 24,440 |
(1) | Pro Forma Adjustments represent: (a) cash proceeds of $1.5 million ($2.0 million AUD) less estimated transaction costs and (b) the related assets and liabilities that were included in the share purchase agreement. |
(2) | Pro Forma Adjustments represent the elimination of historical revenues and expenses contributing to consolidated results relating to the Australian subsidiary. |
(3) | Pro Forma Adjustments do not include revenues and expenses related to the long-term supply and distribution contract entered into by the Company and Global Medical Solutions, Ltd. |
3